Shattuck Labs reported its financial results for the fourth quarter and full year ended December 31, 2024, with a net loss of $75.4 million for the full year. The company's cash and cash equivalents and investments stood at approximately $73.0 million as of December 31, 2024.
The company reiterated its cash runway guidance, stating that its current cash and cash equivalents are expected to fund operations into 2027. This guidance is based on current operational plans and excludes potential future capital raises or business development proceeds.
Shattuck Labs highlighted the termination of its SL-172154 program in 2024, a decision that allowed for a rapid transition to its lead DR3 blocking antibody, SL-325. The company remains on track for an Investigational New Drug (IND) filing for SL-325 in the third quarter of 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.